Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREST: Point-of-care Hepatitis C Testing and Treatment
NCT07560046Phase 4Not yet recruiting
- Sponsor
- Duke University
- Start
- Jan 2027
- Primary completion
- Nov 2030
01
Overview
Phase 4, randomised, open-label trial in hepatitis C (HCV), human immunodeficiency virus infection (HIV) and hepatitis B (HBV) (2 arms), sponsored by Duke University. Primary endpoint: Proportion of participants who complete the Hepatitis C Virus (HCV) care cascade at 24 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
hepatitis C (HCV)human immunodeficiency virus infection (HIV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07560046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560046.